Pubblicazioni 2022

Article information
Received: June 4th, 2022; Revised: June 15th, 2022; Accepted: June 15th, 2022; Published: June 16th, 2022
Sandro Gentile, MD, PhD1,2*; Giuseppina Guarino, MD, PhD2; Ersilia Satta, MD, PhD1; Carmine Romano, BSc1; Felice Strollo, MD, PhD3

1Nefrocenter Research and Nyx Start-up, Naples, Italy

2Department of Internal Medicine, Campania University ‘‘Luigi Vanvitelli’’, Naples, Italy

3Endocrinology and Diabetes Department, IRCCS, San Raffaele Pisana, Rome, Italy

*Corresponding author

Sandro Gentile, MD, PhD Nefrocenter Research and Nyx Start-up, Naples, Italy, Department of Internal Medicine, Campania University ‘‘Luigi Vanvitelli’’, Naples, Italy;
E-mail: s.gentile194@gmail.com

Cite this article
Gentile S, Guarino G, Satta E, Romano C, Strollo F. Why 100-years after the discovery of insulin and the appearance of insulin-induced lipodystrophy: Are we still struggling with this nasty complication? Diabetes Res Open J. 2022; 8(2): 23-29. doi: 10.17140/DROJ-8-156

Ersilia Satta1, Carmelo Alfarone1, Carmine Romano1, Sandro Gentile1 and Giuseppina Guarino2

1Nephrology and Diabetology Research, Nefrocenter Reseaerch S.car, Cava dei Tirreni, Italy and 2Internal medicine, Seconda Università degli Studi di Napoli, Caserta, Italy

Silverio Rotondi1, Ersilia Satta2, Carmine Romano2, Achille Iannone2, Massimo Romano2, Kamela Korreshi1, Lida Tartaglione1, Carmelo Alfarone2 and Sandro Mazzaferro1

1Sapienza University of Rome, Traslational and Precision Medicine, Roma, Italy and 2Nefrocenter Research Network, Nephrology and Diabetology Research, Cava Dei Tirreni, Italy

F. Strollo 1*, S. Gentile2, A. M. V. Pipicelli 3, A. Mambro4, M. Monici5 and P. Magni6,7

1Endocrinology and Metabolism Unit, IRCCS San Raffaele Pisana, Rome, Italy, 2Department of Internal Medicine, Campania

University “Luigi Vanvitelli”, Naples, Italy and Nefrocenter Research Network, Naples, Italy, 3Nephrology, Dialysis and Transplant

Unit, Medical and Surgical Sciences Department, “A. Gemelli” Sacred Heart Catholic University, Rome, Italy, 4Anesthesiology and

Intensive Care Unit, Pertini General Hospital, Rome, Italy, 5Department of Experimental and Clinical Biomedical Sciences “Mario

Serio”, ASA Campus Joint Laboratory, ASA Res. Div, University of Florence, Florence, Italy, 6Department of Pharmacological and

Biomolecular Sciences, Università Degli Studi di Milano, Milan, Italy, 7IRCCS Multimedica Hospital, Sesto San Giovanni, Milan,

Italy

Sandro Gentile . Giuseppina Guarino . Teresa Della Corte . Giampiero Marino . Ersilia Satta .

Maria Pasquarella . Carmine Romano . Carmelo Alfrone . Laura Giordano . Fabrizio Loiacono .

Maurizio Capece . Rossella Lamberti . Felice Strollo on behalf of Nefrocenter and Nyx Start-up, AMDOSDI

Study Group on Injection Techniques, and ANIAD

S. Gentile   G. Guarino   T. Della Corte   E. Satta  

M. Pasquarella   C. Romano   C. Alfrone

Nefrocenter Research and Nyx Start-Up, Naples,

Italy

S. Gentile   G. Guarino   T. Della Corte   G. Marino

Department of Internal Medicine, Campania

University ‘‘Luigi Vanvitelli’’, Naples, Italy

E. Satta

Polyspecialistic Nephrologic Center CNP Srl, Fratta

Maggiore, Italy

L. Giordano

Emodialysis Center Srl, Nefrocenter Network,

Naples, Italy

F. Loiacono

Nefrocenter Research, Naples, Italy

M. Capece

Vomero Center Crisci Bersabea & C SNC,

Nefrocenter Network, Naples, Italy

R. Lamberti

Metelliano Medical Center, Nefrocenter Network,

Naples, Italy

F. Strollo (&)

Endocrinology and Diabetes, IRCCS San Raffaele

Pisana, Rome, Italy

e-mail: felix.strollo@gmail.com

Giuseppina Guarino 1, Felice Strollo 2, Teresa Della-Corte 1,3,* , Ersilia Satta 3, Carmine Romano 3, Carmelo Alfarone 4, Gerardo Corigliano 5, Marco Corigliano 6, Giuseppe Cozzolino 7, Clementina Brancario 7, Carmine Martino 8, Domenica Oliva 9, Agostino Vecchiato 10, Clelia Lamberti 10, Luca Franco 8 and Sandro Gentile 3

1 Departement of Internal Medicine, Campania University “Luigi Vanvitelli”, 80131 Naples, Italy;

giuseppina.guarino@unicampania.it

2 Endocrinology and Diabetes, San Raffaele Pisana Research Institute, 00163 Rome, Italy;

felix.strollo@gmail.com

3 Nefrocenter Research Network & Nyx Research Start-Up, 84013 Naples, Italy; e.satta@nefrocenter.it (E.S.);

croman@libero.it (C.R.); s.gentile1949@gmail.com (S.G.)

4 Nefrocenter Research Network, Diagest Dialysis Unit, 00100 Rome, Italy; carmelo.alfarone@diagest.it

5 Diabetes Unit AID Napoli, 80121 Naples, Italy; gcorigliano@virgilio.it

6 Diabetes Unit AID Oplonti, Torre Annunziata, 80058 Naples, Italy; mcorigliano@inwind.it

7 Diabetes Unit AID Nola, 80035 Nola, Italy; gcozzolino@libero.it (G.C.); clementina.brancario@alice.it (C.B.)

8 Diabetes Unit AID Castellammare di Stabia, 80053 Castellammare di Stabia, Italy;

carminemartino@msn.com (C.M.); luca.francomd@gmail.com (L.F.)

9 Diabetes Unit AID Cava de’ Tirreni, 84013 Cava de’ Tirreni, Italy; domenica_oliva@libero.it

10 Diabetes Unit AID Nocera Inferiore, 84014 Nocera Inferiore, Italy; a.vecchiato@gmail.com (A.V.);

cleo.lamberti@libero.it (C.L.)

* Correspondence: tere.dellacorte@gmail.com

Genital Infection Risk Profile in Post-menopausal Women with Type 2 Diabetes Mellitus on Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors

Gentile S1,2, Guarino G1, Della Corte T1,2, Satta E2-4, Pipicelli AMV5, Romano C2, Alfarone C2, Lamberti R6, Di Maio A6 and Strollo F7*

1Campania University “Luigi Vanvitelli”, Naples, Italy

2Nefrocenter Research and Nyx Start-UP, Naples, Italy

3Haemodialysis Center s.r.l. Nefrocenter Network, Naples, Italy

4Polyspecialist Nephrology Center CNP Srl, Nefrocenter Network SRL,

Frattamaggiore, Italy

5Nephrology, Dialysis and Transplant Unit, Medical and Surgical Science

Department, “A. Gemelli” University Polyclinic IRCCS Foundation, Catholic

University of the Sacred Heart, Rome, Italy

6Metelliano Medical Center, Nefrocenter Network, Naples, Italy

7IRCCS San Raffaele Pisana, Rome, Italy

*Corresponding Author: Strollo F, IRCCS San Raffaele Pisana, Rome, Italy.

Email: felix.strollo@gmail.com

Comment on the article “Determination of insulin-related lipohypertrophy frequency and risk factors in patients with diabetes”

S. Gentile, G. Guarino, E. Satta et al., Comment on the article Determination of insulin related lipohypertrophy frequency and risk factors in patients with diabetes, Endocrinología, Diabetes y Nutrición,

References1. Korkmaz FN, Canpolat GA, Güllü S. Determination of insulin-related lipohypertrophy frequency and risk factors in patient swith diabetes Determinación de la frecuencia y los factores de riesgo de la lipohipertrofia relacionada con la insulina en pacientes con diabetes. Endocrinol Diab y Nutrición. 2021,http://dx.doi.org/10.1016/j.endinu.2021.07.002. First online25 August.

2. Gentile S, Strollo F, Guarino G. Diabetologists; nurses. Why are so huge differences reported in the occurrence rate of skin lipohypertrophy? Does it depend on method defects or on lack of interest? Diabetes Metab Syndr. 2019;13(1):682—6,http://dx.doi.org/10.1016/j.dsx.2018.11.042. Epub 2018 Nov16. PMID: 30641790.

3. Gentile S, Strollo F, Della Corte T, Marino G, GuarinoG. Insulin related lipodystrophic lesions and hypoglycemia:Double standards? Diabetes Metab Syndr. 2018;12(5):813—8,http://dx.doi.org/10.1016/j.dsx.2018.04.023. Epub 2018 Apr10. PMID: 29703450.

4. Ansari AM, Osmani L, Matsangos AE, Li QK. Current insight in the localized insulin-derived amyloidosis (LIDA): clinico-pathological characteristics and differential diagnosis.Pathol Res Pract. 2017;213(10):1237—41, http://dx.doi.org/10.1016/j.prp.2017.08.013. Epub 2017 Sep 1. PMID: 28935176.

5. Frid AH, Kreugel G, Grassi G, Halimi S, Hicks D, HirschLJ, et al. New insulin delivery recommendations. MayoClin Proc. 2016;91(9):1231—55, http://dx.doi.org/10.1016/j.mayocp.2016.06.010. PMID: 27594187.

6. Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence andrisk factors of lipohypertrophy in insulin-injecting patients withdiabetes. Diabetes Metab. 2013;39:445—50.

7. Gentile S, Guarino G, Della Corte T, Marino G, Satta E,Pasquarella M, et al. The durability of an intensive structurededucation-based rehabilitation protocol for best insulin injectionpractice: the ISTERP-2 study. Diabetes Ther. 2021;12(9):2557—69,http://dx.doi.org/10.1007/s13300-021-01108-9. PMID: Epub2021 Aug 12. PMID: 34383261.

Sandro Gentilea,b,∗, Giuseppina Guarinoa, Ersilia Sattab,Felice StrollocaVanvitelli University, School of Medicine, Naples, ItalybNefrocenter Research and Nyx Start-up, Naples, ItalycIRCCS San Raffaele Pisana, Rome, Italy∗

Corresponding author.E-mail address: s.gentile1949@gmail.com (S. Gentile).2

https://doi.org/10.1016/j.endinu.2021.09.016

Acknowledgment: Special thanks are due to Paola Murano for her complimentary editorial assistance.

Kidney and lung in pathology: mechanisms and clinical implications

Ersilia Satta,1 Carmelo Alfarone,2 Alfonso De Maio,3 Sandro Gentile,1 Carmine Romano,1 Mario Polverino,1 Francesca Polverino4

1Nefrocenter Research S.c.arl, Cava de’ Tirreni (SA), Italy

2Betadial Srl, Dialysis Center, Nefrocenter, Cava de’ Tirreni (SA), Italy

3CMM Srl, Dialysis Center, Nefrocenter, Cava de’ Tirreni (SA), Italy

4Asthma and Airway Disease Research Center, Department of Medicine, University of Arizona, Tucson, AZ, USA

Monocyte to HDL ratio: a novel marker of resistant hypertension in CKD patients

Guido Gembillo1,2   Rossella Siligato1   Valeria Cernaro1   Ersilia Satta2   Giovanni Conti3   Antonino Salvo1 Adolfo Romeo1   Vincenzo Calabrese1   Giovanna Sposito4,5   Guido Ferlazzo4,5   Domenico Santoro1

1 Unit of Nephrology and Dialysis, Department of Clinical

and Experimental Medicine, University of Messina, Via

Consolare Valeria, 98125 Messina, Italy

2 Department of Biomedical, Dental, Morphological

and Functional Imaging Sciences, University of Messina,

Messina, Italy

3 Nefrocenter Research Network, Naples, Italy

4 Pediatric Nephrology Unit, AOU Policlinic “G Martino”,

University of Messina, 98125 Messina, Italy

5 Laboratory of Immunology and Biotherapy, Department

of Human Pathology, University of Messina, Messina, Italy

Heart Failure with Preserved Ejection Fraction

Vincenzo Maria Monda . Sandro Gentile . Francesca Porcellati . Ersilia Satta . Alessandro Fucili . Marcello Monesi . Felice Strollo

V. M. Monda
Diabetes Unit ‘‘Santissima Annunziata’’ Hospital
Cento, Ferrara, Italy
e-mail: v.monda@ausl.fe.it

S. Gentile (&)
Department of Precision Medicine, Campania
University ‘‘Luigi Vanvitelli’’, Naples, Italy
e-mail: s.gentile1949@gmail.com

S. Gentile
Nefrocenter Research Network, Cava de´ Tirreni, Italy

F. Porcellati
Section of Internal Medicine, Endocrinology and
Metabolism, Department of Medicine, Perugia
University School of Medicine, Perugia, Italy
e-mail: f.porcellati.fp@gmail.com

E. Satta
Polyspecialistic Nephrologic Center CNP Srl, Fratta
Maggiore, Italy

E. Satta
Nefrocentre Research Network, Cava de´ Tirreni, Italy
e-mail: e.satta@nefrocenter.it

A. Fucili
Cardiovascular Research Center, Ferrara University,
Ferrara, Italy
e-mail: fucilialessandro@gmail.com

M. Monesi
Diabetes Unit ‘‘Sant’Anna’’ Hospital Ferrara, Ferrara,
Italy
e-mail: m.monesi@ausl.fe.it

F. Strollo
Department of Endocrinology and Diabetes, IRCCS
San Raffaele Pisana, Rome, Italy
e-mail: felix.strollo@gmail.com

A Journey Through Guidelines, Consensus, Curriculum of Educators and Clinical Practice on Insulin-Induced Skin Lipohypertrophy: From the Earth to the Moon

Sandro Gentile1,2, 3, Ersilia Satta1,2,4, Giuseppina Guarino1,2, 3, Carmine Romano1,2, Adalgisa Maffettone1,5, Erika Eliana Henke1,5, Elvira Donnarumma1,5, Romina Castellano1,5, Salvatore Izzo1,5,
Iolanda Manzo1,5, Felice Strollo1,6

1Nefrocenter Research and Nyx Start-up Study Group, AMD-OSDI* Study Group on Injection Techniques, and ANIAD**

2Nefrocenter Research and Nyx Start-Up, Naples, Italy

3Department of Precision Medicine, Campania University ‘‘Luigi Vanvitelli’’, Naples, Italy

4Polyspecialistic Nephrologic Center CNP Srl, Fratta Maggiore, Italy

5Department of Biology and Bichemistry “Maiello”, Nefrocenter Research Network, Naples, Italy

6Department of Endocrinology and Diabetes, IRCCS San Raffaele Pisana, Rome, Italy

Correspondence: s.gentile1949@gmail.com

* AMD = Associazione Medici Diabetologi (Italian Association of

Diabetes Specialists) – OSDI = Operatori Sanitari di Diabetologia

Italiani (Italian Diabetes Healthcare Professionals)

**ANIAD = Associazione Nazionale Italiana Atleti Diabetici (Italian

National Association of Athletes with Diabetes)

STUDIO AVE – Revisione narrativa sulla fistola artero-venosa per emodialisi

Ersilia Satta1,2, Carmine Romano2, Carmelo Alfarone 2, Ilaria Raiola2, Lisa Scarpati2, Fabrizio Lo Iacono2, Monica Di Maio2, Luigi Russo3, Domenico Russo4, Margherita Maria Pagliuca5 

1 CNP, Centro Nefrologico Polispecialistico, Nefrocenter srl 2 Nefrocenter Research 3 Nefrologia. Ospedale del Mare. Napoli 4 Dipartimento di Sanità Pubblica. Università di Napoli, Federico II 5 Department of Management Studies and Quantitative Methods (DISAQ) 

University of Naples “Parthenope” 

Corrispondenza a: Ersilia Satta Nefrocenter Research, Torre Del Greco. Napoli Mobile: 3395703091 E-mail: e.satta@nefrocenter.it 

Abstract: The number of adult individuals with insulin-treated diabetes mellitus (DM) is steadily increasing worldwide. The main local complications of insulin injection are lipohypertrophies (LHs), i.e., subcutaneous nodules consisting of aggregates of macro-adipocytes and fibrin. These nodules result from errors repeatedly made by patients while injecting insulin. Despite being very common, LH lesions/nodules due to incorrect insulin injection techniques are often flat and hardly visible and thus require thorough deep palpation examination and ultrasonography (US) for detection. Identifying LHs is crucial, especially in elderly and frail subjects, because they may eventually result in poor diabetes control due to associated unpredictable insulin release patterns. Raising awareness of the adequate detection of LHs and their clinical consequences is crucial and urgent. A call to action is required on this topic at all levels of undergraduate and postgraduate education.

Felice Strollo 1, Ersilia Satta 2 and Sandro Gentile 2,3,* 1 Endocrinology and Diabetes, IRCCS San Raffaele Pisana, I-00163 Rome, Italy 2 Nefrocenter Research & Nyx Start-Up, I-80030 Naples, Italy 3 Department of Internal Medicine, Luigi Vanvitelli University of Campania, I-50138 Naples, Italy *

Correspondence: s.gentile1949@gmail.com

Validation and applicability of an innovative monitoring system for vascular access in haemodialysis (HD). Multicentre study.

Silverio Rotondi1, Ersilia Satta2, Carmine Romano2, Achille Iannone2, Massimo Romano2, Kamela Korreshi1, Lida Tartaglione1, Carmelo Alfarone2 and Sandro Mazzaferro1

1 Sapienza University of Rome, Traslational and Precision Medicine, Roma, Italy 2 Nefrocenter Research Network, Nephrology and Diabetology Research, Cava Dei Tirreni, Italy

Sglt-2i in diabetici tipo2 con ridotta funzione renale e pregresso evento C-V

Satta E.1, Strollo F.2, Romano C.1, Guarino G.3, Maffettone G., Donnarumma E, Henke E., Castellano R, Raiola I, Leone L. Vetrano A., Gembillo G.4, Gentile S.1,3

1 Nefrocenter Research Network, Cava dè Tirreni (SA). 2. Elle D, San Raffaele Pisana, Roma, Istituto di Endocrinologia. 3 Università Vanvitelli, Napoli, Istituto di Medicina Interna. 4 Universita degli studi di Messina, Istituto di Nefrologia.

La fosfaturia quale indicatore precoce delle alterazioni del metabolismo minerale della malattia renale cronica.

Di Iorio B. 1, Russo D. 2, Bruzzese D. 1, Satta E. 3 Battaglia Y. 4,5

1. Dipartimento di Nefrologia, Ospedale di Avellino. 2. Dipartimento di Sanità Pubblica, Università FEDERICO II, Napoli. 3.Nefrocenter Research, Torre del Greco (Napoli). 4. Dipartimento di Medicina, Università di Verona. 5. Ospedale Pederzoli, Peschiera del Garda (Verona).

Tosse e sintomi respiratori nei pazienti emodializzati.

Satta E.1, Romano C.1, Gentile S.1, Puce M.1, Erbaggio G.1 Gembillo G.3, Polverino M.1 and Polverino F.4

1. Nefrocenter e Nefrocenter Research S.c.arl, Torre del Greco, Italy. 2. Betadial Srl, Dialysis Center, Nefrocenter, Cava dei Tirreni, Italy. 3. Institute of Nephrology,University of Messina. 4. Department of Medicine, Baylor College of Medicine, and Center for Translational Research Houston, TX, USA

Efficacy and safety of a polysaccharide-based natural substance complex, in the treatment of metabolic risk factors associated with Metabolic Syndrome

Giuseppina Guarino1, Felice Strollo2, Peter Malfertheiner3, 4, Teresa Della Corte1, 5, Stefano Stagi6, Mario Masarone7*, Sandro Gentile1, 5

1 University of Campania Luigi Vanvitelli, Italy,
2 San Raffaele Pisana (IRCCS), Italy,
3 Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University of Magdeburg, Germany,
4 Department of Internal Medicine II, LMU University Clinic, Germany,
5 Nefrocenter Research Network & Nyx Research Start-Up, Italy,
6 Health Sciences Department, University of Florence, Anna Meyer Children’s University Hospital, Italy,
7 Department of Medicine, Surgery and Dentistry, University of Salerno, Italy

Efficacy and safety of a polysaccharide-based natural substance complex, in the treatment of metabolic risk factors associated with Metabolic Syndrome

Giuseppina Guarino1, Felice Strollo2, Peter Malfertheiner3, 4, Teresa Della Corte1, 5, Stefano Stagi6, Mario Masarone7*, Sandro Gentile1, 5

1 University of Campania Luigi Vanvitelli, Italy,
2 San Raffaele Pisana (IRCCS), Italy,
3 Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University of Magdeburg, Germany,
4 Department of Internal Medicine II, LMU University Clinic, Germany,
5 Nefrocenter Research Network & Nyx Research Start-Up, Italy,
6 Health Sciences Department, University of Florence, Anna Meyer Children’s University Hospital, Italy,
7 Department of Medicine, Surgery and Dentistry, University of Salerno, Italy